associated genes have been identified, including the gene encoding cardiac troponin T type-2 (TNNT2). We examined polymorphisms of the TNNT2 gene in a Kazak family from Xinjiang, China, and in idiopathic DCM (IDCM) patients of both Kazak and Han ethnicity.
OBJECTIVES To investigate the immediate and short-term therapeutic efficacy and feasibility of coil embolization of a targeted septal artery in patients with hypertrophic obstructive cardiomyopathy (HOCM).
METHODS Four patients with hypertrophic obstructive cardiomyopathy refractory to medication were chosen, and treated with coil embolization of a targeted septal artery. Preoperative, intraoperative and postoperative left ventricular outflow tract pressure gradient (LVOTPG), septal thickness and systolic anterior motion of mitral (SAM) phenomenon were compared. Postoperative complications and improvement of clinical symptoms were observed.
RESULTS Embolization of the targeted septal branch was successfully performed in 4 patients. Compared with preoperative LVOTPG of patients after balloon pressure and complete occlusion were significantly lower(92.50AE26.30 vs. 38.00AE6.93 and 28.25AE6.24 mmHg; P <0.05, respectively). The average septal thickness of patients at one month after operation was not statistically significant difference compared with the preoperative value(18.40AE2.36 vs. 18.68AE2.42 mm; P >0.05, respectively). Follow-up of the 4 cases at 1 month after operation revealed remarkable attenuation of SAM phenomenon. We did not detect ventricular tachycardia and atrioventricular block. Postoperative NYHA classification were significantly lower than baseline (3.00AE0.82 vs. 1.50AE0.58; P <0.05, respectively).
CONCLUSIONS The study showed treatment for hypertrophic obstructive cardiomyopathy by coil embolization of a targeted septal artery is feasible.In the treatment of HOCM, coil embolization of a targeted septal artery can significantly reduce LVOTPG and improve clinical symptoms.
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The effects of smoking and drinking on all-cause mortality in patients with dilated cardiomyopathy: a single-center cohort study OBJECTIVES Recent studies have shown that smoking and drinking are associated with poorer outcomes in patients with cardiomyopathy. The purpose of this study was to determine all-cause mortality in dilated cardiomyopathy (DCM) associated with smoking and drinking.
METHODS An observational cohort study was undertaken in DCM patients from November 2003 to September 2011. A total of 1118 patients were enrolled, with a mean follow-up of 3.5AE2.3 years. Standard demographics were obtained, and transthoracic echocardiography and routine blood testing were performed shortly after admission. Outcome assessment was based on the all-cause death after admission.
RESULTS
The patients were divided into three groups: non-smokers (n ¼593), mild to moderate smokers (n ¼159) and heavy smokers (n ¼366). The all-cause mortality rates showed no differences between the three groups (23.8%, 20.8% and 24%, respectively; log-rank c 2 ¼1.281, P ¼0.527). There was also no significant difference in mortality between non-drinkers (n ¼747), mild drinkers (n ¼142) and moderate drinkers (n ¼229) (23.7%, 23.2% and 22.3%, respectively; log-rank c 2 ¼2.343, P ¼0.310). In the Cox analysis, neither the smoking (HR 0.971, P ¼0.663) nor the drinking status (HR 0.891, P ¼0.140) was a significant independent predictor of all-cause mortality in patients with DCM. CONCLUSIONS In conclusion, there were no significant differences in mortality between the smoking-and drinking-related patient groups, indicating no effect of smoking and drinking on all-cause mortality in patients with DCM in the present large-scale study.
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Correlation between Tei index and B-natriuretic peptide in dilated cardiomyopathy patients
